Short-and long-term survival in treated elderly hypertensive patients with or without diabetes: Findings from the second Australian national blood pressure study

American Journal of Hypertension

Volumn 27, Issue 2, 2014, Pages 199-206

  Chowdhury, Enayet K ^a   Owen, Alice ^a   Ademi, Zanfina ^a,b   Krum, Henry ^a   Johnston, Colin I ^c   Wing, Lindon M H ^d   Nelson, Mark R ^e   Reid, Christopher M ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

^e UNIVERSITY OF TASMANIA   (Australia)

Author keywords

blood pressure; elderly; hypertension; mortality; newly diagnosed diabetes; preexisting diabetes.

Indexed keywords

ENALAPRIL; GLUCOSE; HYDROCHLOROTHIAZIDE;

AGED; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INCIDENCE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SHORT TERM SURVIVAL; SYSTOLIC BLOOD PRESSURE; VERY ELDERLY;

BLOOD PRESSURE; ELDERLY; HYPERTENSION; MORTALITY; NEWLY DIAGNOSED DIABETES; PREEXISTING DIABETES.;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; AUSTRALIA; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INCIDENCE; SODIUM CHLORIDE SYMPORTER INHIBITORS; SURVIVAL ANALYSIS;

EID: 84891615300     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt212     Document Type: Article

References (37)

1. Hu FB. Globalization of diabetes. Diabetes Care 2011; 34:1249-1257.
2. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease. Hypertension 2001; 37:1053-1059.
3. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994; 23:145-158.
4. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999; 33:1130-1134.
5. Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412-419.
6. Brenner B, Cooper M, De Zeeuw D, Keane W, Mitch W, Parving H, Remuzzi G, Snapinn S, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
7. Brown M, Palmer C, Castaigne A, de Leeuw P, Mancia G, Rosenthal T, Ruilope L. Morbidity and mortality in patients randomised to doubleblind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000; 356:366-372.
8. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen S, Lindholm L, Syvertsen J, Lanke J, deFaire U, Dahlof B, Karlberg B; for the NORDIL study group. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359-365.
9. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000; 355:253-258.
10. Pahor M, Psaty B, Furberg C. New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes. J Cardiovasc Pharmacol 1998; 32:S18-S23.
11. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
12. Grossman E, Messerli FH. Management of blood pressure in patients with diabetes. Am. J. Hypertens 2011; 24:863-875.
13. Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006; 29:1065-1070.
14. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and anti hypertensive drugs. J Hypertens 2006; 24:3-10.
15. Moser M. Is new-onset diabetes of clinical significance in treated hypertensive patients? J Clin Hypertens (Greenwich, Conn.) 2006; 8:126-132.
16. Smith NL, Lumley T, Barzilay JI, Enquobahrie D, Kronmal R, Psaty BM. New-onset diabetes and risk of all-cause and cardiovascular mortality-the cardiovascular health study. Diabetes Care 2006; 29:2012-2017.
17. Eberly LE, Cohen JD, Prineas R, Yang LF, Multiple Risk Factor I. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality-the Multiple Risk Factor Intervention Trial experience. Diabetes Care 2003; 26:848-854.
18. Burke JP, O'Brien P, Ransom J, Palumbo PJ, Lydick E, Yawn BP, Joseph Melton L, Leibson CL. Impact of case ascertainment on recent trends in diabetes incidence in Rochester, Minnesota. Am J Epidemiol 2002; 155:859-865.
19. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults-the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21:518-524.
20. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2004;365:217-223.
21. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592.
22. Reid CM. Australian comparative outcome trial of angiotensin-converting enzyme inhibitor-and diuretic-based treatment of hypertension in the elderly (ANBP2): objectives and protocol. Clin Exp Pharmacol Physiol 1997; 24:188-192.
23. Stata Statistical Software: Release 11 [computer program]. StataCorp LP: College Station, TX, 2009.
24. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester PO, Björck J-E. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-616.
25. Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial population. Hypertension 2007; 50:467-473.
26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
27. Magliano DJ, Barr ELM, Zimmet PZ, Cameron AJ, Dunstan DW, Colagiuri S, Jolley D, Owen N, Phillips P, Tapp RJ, Welborn TA, Shaw JE. Glucose indices, health behaviors, and incidence of diabetes in Australia: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2008; 31:267-272.
28. Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR, Anglo-Scandinavian Cardiac O. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-blood pressure lowering arm and the relative influence of antihypertensive medication. Diabetes Care 2008; 31:982-988.
29. Aksnes TA, Kjeldsen SE, Rostrup M, Storset O, Hua TA, Julius S. Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial. J Hum Hypertens 2008; 22:520-527.
30. Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, Giannattasio C, Grassi G, Sega R. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J Hypertens 2008; 26:1602-1611.
31. Wilson PWF, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112:3066-3072.
32. Australian Institute of Health and Welfare. Diabetes Prevalence in Australia: Detailed Estimates for 2007-08. Diabetes Series No. Cat. No. CVD 56. AIHW: Canberra, Australia, 2011.
33. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J, Investigators DT. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004; 47:1519-1527.
34. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J, Grp ACR. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment-a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166:2191-2201.
35. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR, Grp SCR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005; 95:29-35.
36. Almgren T, Wilhelmsen L, Samuelsson O, Himmelmann A, Rosengren A, Andersson OK. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens. 2007; 25:1311-1317.
37. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, Norgiolini S, Bracco C, Porcellati C. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43:963-969.